CN Patent

CN105367515B — 一种氢溴酸沃替西汀α晶型的制备方法

Assigned to BEIJING BEILU PHARMACEUTICAL Co Ltd · Expires 2017-10-27 · 9y expired

What this patent protects

本发明公开了一种氢溴酸沃替西汀α晶型的制备方法。其包括下述步骤：将氢溴酸沃替西汀一仲丁醇合物去除仲丁醇，得到所述的氢溴酸沃替西汀α晶型即可。该方法去溶剂化温度低，制得的氢溴酸沃替西汀α晶型的晶型纯度高、粒度适宜、适于工业化生产。

USPTO Abstract

本发明公开了一种氢溴酸沃替西汀α晶型的制备方法。其包括下述步骤：将氢溴酸沃替西汀一仲丁醇合物去除仲丁醇，得到所述的氢溴酸沃替西汀α晶型即可。该方法去溶剂化温度低，制得的氢溴酸沃替西汀α晶型的晶型纯度高、粒度适宜、适于工业化生产。

Drugs covered by this patent

vortioxetine-hydrobromide (VORTIOXETINE HYDROBROMIDE)

Patent Metadata

Patent number: CN105367515B
Jurisdiction: CN
Classification: —
Expires: 2017-10-27
Drug substance claim: No
Drug product claim: No
Assignee: BEIJING BEILU PHARMACEUTICAL Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.